Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.

نویسندگان

  • David J Seiffge
  • Robbert-JanVan Hooff
  • Christian H Nolte
  • Yannick Béjot
  • Guillaume Turc
  • Benno Ikenberg
  • Eivind Berge
  • Malte Persike
  • Nelly Dequatre-Ponchelle
  • Daniel Strbian
  • Waltraud Pfeilschifter
  • Andrea Zini
  • Arnstein Tveiten
  • Halvor Næss
  • Patrik Michel
  • Roman Sztajzel
  • Andreas Luft
  • Henrik Gensicke
  • Christopher Traenka
  • Lisa Hert
  • Jan F Scheitz
  • Gian Marco De Marchis
  • Leo H Bonati
  • Nils Peters
  • Andreas Charidimou
  • David J Werring
  • Frederick Palm
  • Matthias Reinhard
  • Wolf-Dirk Niesen
  • Takehiko Nagao
  • Alessandro Pezzini
  • Valeria Caso
  • Paul J Nederkoorn
  • Georg Kägi
  • Alexander von Hessling
  • Visnja Padjen
  • Charlotte Cordonnier
  • Hebun Erdur
  • Philippe A Lyrer
  • Raf Brouns
  • Thorsten Steiner
  • Turgut Tatlisumak
  • Stefan T Engelter
چکیده

BACKGROUND We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). METHODS AND RESULTS This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICHany), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICHECASS-II) and the National Institute of Neurological Disorders and Stroke (NINDS) thrombolysis trial (sICHNINDS); and (2) death (at 3 months). Cohorts were compared by using propensity score matching. Our NOAC cohort comprised 78 patients treated with IVT/IAT and the comparison groups of 441 VKA patients and 8938 no-OAC patients. The median time from last NOAC intake to IVT/IAT was 13 hours (interquartile range, 8-22 hours). In VKA patients, median pre-IVT/IAT international normalized ratio was 1.3 (interquartile range, 1.1-1.6). ICHany was observed in 18.4% NOAC patients versus 26.8% in VKA patients and 17.4% in no-OAC patients. sICHECASS-II and sICHNINDS occurred in 2.6%/3.9% NOAC patients, in comparison with 6.5%/9.3% of VKA patients and 5.0%/7.2% of no-OAC patients, respectively. At 3 months, 23.0% of NOAC patients in comparison with 26.9% of VKA patients and 13.9% of no-OAC patients had died. Propensity score matching revealed no statistically significant differences. CONCLUSIONS IVT/IAT in selected patients with ischemic stroke under NOAC treatment has a safety profile similar to both IVT/IAT in patients on subtherapeutic VKA treatment or in those without previous anticoagulation. However, further prospective studies are needed, including the impact of specific coagulation tests.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

O10: Thrombo-Inflammation in Acute Ischemic Stroke

Ischemic stroke has been classified as a merely thrombotic disease, so the main goal of its treatment is the recanalization of the occluded vasculature. However, despite fast restoration of blood circulation, progressive stroke still develops in many patients, which has led to the concept of reperfusion injury. &nbsp;The underlying mechanism is only partly known. Though, it is accepted now, tha...

متن کامل

Oral anticoagulants--a frequent challenge for the emergency management of acute ischemic stroke.

BACKGROUND The emergency management of patients with acute ischemic stroke (IS) using oral anticoagulants (OAC) represents a great challenge. Effective anticoagulation predisposes to bleeding and represents a contraindication for systemic thrombolysis. However, patients on OAC can receive intravenous thrombolysis with recombinant tissue-type plasminogen activator if the international normalized...

متن کامل

What if a patient with atrial fibrillation and anticoagulant treatment is suffering from acute ischemia stroke?

Accessible online at: www.karger.com/ced Atrial fibrillation (AF) is responsible for about 25% of all ischemic strokes [1] , and the risk of stroke attributed to AF increases with age [2] . AF was associated with increased stroke severity, high frequency of complications and poor outcome [3–5] . Thrombolytic therapy with intravenous tissue plasminogen activator (tPA) is of net benefit in patien...

متن کامل

Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study.

BACKGROUND AND PURPOSE The best time for administering anticoagulation therapy in acute cardioembolic stroke remains unclear. This prospective cohort study of patients with acute stroke and atrial fibrillation, evaluated (1) the risk of recurrent ischemic event and severe bleeding; (2) the risk factors for recurrence and bleeding; and (3) the risks of recurrence and bleeding associated with ant...

متن کامل

Intracranial Hemorrhage after Endovascular Revascularization for Acute Ischemic Stroke

Objective: Intracranial hemorrhage (ICH) after endovascular revascularization (ER) for acute ischemic stroke is associated with poor outcome. In this study, we examined the risk factors for postoperative ICH in patients who underwent ER in our hospital. Methods: We investigated the incidence/type of postoperative ICH and risk factors in 157 patients who underwent ER in our hospital from July 20...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Circulation

دوره 132 13  شماره 

صفحات  -

تاریخ انتشار 2015